Novartis keeps its CAR-T lead with positive Phase II data

Damian Garde

, leading a pack of companies developing genetically engineered T cells to fight cancer, unveiled more promising on its II treatment as it wends toward an FDA filing.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS